NetworkNewsBreaks – Trxade Group Inc. (TRXD) Rec
Post# of 174
Integrated pharmaceutical services company Trxade Group (OTCQB: TRXD) recently received approval from the Securities and Exchange Commission (“SEC”) on its S-1 Registration Statement concerning the intermittent resale of TRXD’s stock by its shareholders. An article discussing the company reads, “‘We have been working diligently on our registration statement since April 2019, and we are extremely delighted to announce that the SEC has informed the company that its S-1 Registration Statement is now effective. The S-1 Registration Statement lays the groundwork for transparency, oversight and financing program,’ CEO Suren Ajjarapu stated in a news release (http://nnw.fm/NmCZ1). . . . Trxade is building a reputation as ‘the trusted pharmaceutical marketplace’ in an effort to provide the more than 10,500 independent pharmacies that subscribe to its software trading platform with competitive drug-pricing options and reduced product shortages while working reliably within U.S. pharmaceutical distribution channels and without production modification.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer